Close Menu

Europe

In PLOS this week: nucleosome structure linked to UV-induced melanoma mutational signatures, genetic diversity and population structure in reindeer, and more.

The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.

The company plans to use the funds to drive commercialization of its recently launched Fluidity One instrument and develop other products in its pipeline.

A GWAS meta-analysis involving hundreds of thousands of cases and controls led to new and known gallstone disease-associated variants at 28 loci.

See What They Said

Following a pilot project, Genome Biology is to adopt a transparent peer review process at the beginning of 2019.

Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.

Respondents to GenomeWeb's salary survey reported variations in their salaries that varied by sector.

The researchers reported that targeting HDAC4 in the patient-derived neurons appeared to correct the expression of genes that differed in the disease state.

The UK developers believe that their device has the potential for multiplex testing at the point of care using solid-state nanopore sensing with DNA probes.

The firms will begin a prospective lung cancer study using Biocartis' Idylla EGFR mutation test in European countries, including Belgium, France, Germany, and Italy.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.